CRB3

Across TCGA pan-cancer cohorts, CRB3 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of CRB3’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CRB3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CRB3 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

BLCA, UCEC, and BRCA are the cancer types where CRB3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRB3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+2.272	.023	8	view →
UCEC	All	All	+2.585	<.001	6	view →
BRCA	All	III,IV	+1.749	<.001	6	view →
LIHC	All	All	+0.645	<.001	6	view →
THCA	All	All	+0.201	.020	4	view →
CHOL	All	All	+2.027	<.001	3	view →
STAD	All	All	+1.206	.008	3	view →
KIRP	Female	II,III,IV	+0.567	.030	3	view →
PRAD	All	All	+0.468	<.001	2	view →
LUSC	All	All	−0.406	<.001	2	view →
COAD	Female	III,IV	+0.469	.048	1	view →
LUAD	Male	All	−0.401	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

CRB3–BLCA

Open the BLCA breakdown →